CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Switching From Reference to Biosimilar Etanercept for Patients with Plaque Psoriasis

Last updated: February 18, 2021
Project Number: RB1553-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of switching from reference to biosimilar etanercept in adult or pediatric patients with plaque psoriasis?

Key Message

Two randomized controlled trials were identified regarding the clinical effectiveness of switching from reference etanercept to biosimilar etanercept in adult or pediatric patients with plaque psoriasis.